Trade Biotage - BIOT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 1.8 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.021948% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000275% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SEK | ||||||||
Margin | 5% | ||||||||
Stock exchange | Sweden | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biotage AB ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 124.2 |
Open* | 121.5 |
1-Year Change* | -33.02% |
Day's Range* | 119 - 124.1 |
52 wk Range | 83.05-199.30 |
Average Volume (10 days) | 188.37K |
Average Volume (3 months) | 5.14M |
Market Cap | 10.11B |
P/E Ratio | 46.26 |
Shares Outstanding | 80.01M |
Revenue | 1.60B |
EPS | 2.73 |
Dividend (Yield %) | 1.26683 |
Beta | 1.20 |
Next Earnings Date | Feb 15, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 124.2 | 3.6 | 2.99% | 120.6 | 126.8 | 120.5 |
Dec 7, 2023 | 122.8 | -0.9 | -0.73% | 123.7 | 124.1 | 119.9 |
Dec 6, 2023 | 125.4 | 3.4 | 2.79% | 122.0 | 125.5 | 120.1 |
Dec 5, 2023 | 121.1 | 0.3 | 0.25% | 120.8 | 122.3 | 118.7 |
Dec 4, 2023 | 121.2 | -1.6 | -1.30% | 122.8 | 124.7 | 120.1 |
Dec 1, 2023 | 122.8 | -2.8 | -2.23% | 125.6 | 130.2 | 122.8 |
Nov 30, 2023 | 131.2 | 3.9 | 3.06% | 127.3 | 131.2 | 125.2 |
Nov 29, 2023 | 129.4 | 5.9 | 4.78% | 123.5 | 129.6 | 123.5 |
Nov 28, 2023 | 126.5 | 1.8 | 1.44% | 124.7 | 127.6 | 122.7 |
Nov 27, 2023 | 124.5 | -1.3 | -1.03% | 125.8 | 127.6 | 124.0 |
Nov 24, 2023 | 128.0 | 1.7 | 1.35% | 126.3 | 128.0 | 124.5 |
Nov 23, 2023 | 126.2 | 0.9 | 0.72% | 125.3 | 126.6 | 123.9 |
Nov 22, 2023 | 125.4 | 3.5 | 2.87% | 121.9 | 126.3 | 121.9 |
Nov 21, 2023 | 121.8 | -2.5 | -2.01% | 124.3 | 127.1 | 121.0 |
Nov 20, 2023 | 124.4 | -2.9 | -2.28% | 127.3 | 130.0 | 123.3 |
Nov 17, 2023 | 127.2 | 9.7 | 8.26% | 117.5 | 127.4 | 117.5 |
Nov 16, 2023 | 121.3 | 2.6 | 2.19% | 118.7 | 121.4 | 116.5 |
Nov 15, 2023 | 118.7 | -0.4 | -0.34% | 119.1 | 124.3 | 117.5 |
Nov 14, 2023 | 118.7 | 0.5 | 0.42% | 118.2 | 121.3 | 116.6 |
Nov 13, 2023 | 118.7 | -1.1 | -0.92% | 119.8 | 123.4 | 118.3 |
Biotage Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, February 15, 2024 | ||
Time (UTC) 14:00 | Country SE
| Event Q4 2023 Biotage AB Earnings Call Q4 2023 Biotage AB Earnings CallForecast -Previous - |
Thursday, April 25, 2024 | ||
Time (UTC) 10:59 | Country SE
| Event Q1 2024 Biotage AB Earnings Release Q1 2024 Biotage AB Earnings ReleaseForecast -Previous - |
Friday, April 26, 2024 | ||
Time (UTC) 15:00 | Country SE
| Event Biotage AB Annual Shareholders Meeting Biotage AB Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1566 | 1232 | 1092.28 | 1101.37 | 910.896 |
Revenue | 1566 | 1232 | 1092.28 | 1101.37 | 910.896 |
Cost of Revenue, Total | 618 | 477 | 425.55 | 415.963 | 354.27 |
Gross Profit | 948 | 755 | 666.728 | 685.41 | 556.626 |
Total Operating Expense | 1239 | 961 | 886.093 | 893.253 | 738.418 |
Selling/General/Admin. Expenses, Total | 481 | 374 | 336.94 | 360.028 | 313.127 |
Research & Development | 68 | 56 | 44.102 | 49.733 | 43.101 |
Depreciation / Amortization | 89 | 65 | 66.449 | 65.132 | 34.032 |
Interest Expense (Income) - Net Operating | -35 | -16 | -19.352 | -2.41 | -14.681 |
Unusual Expense (Income) | 2.5 | 2.5 | |||
Other Operating Expenses, Total | 18 | 5 | 32.404 | 2.307 | 6.069 |
Operating Income | 327 | 271 | 206.185 | 208.12 | 172.478 |
Interest Income (Expense), Net Non-Operating | -7 | -12 | -8.901 | 3.949 | 3.811 |
Other, Net | 28 | 10 | 25.445 | -0.077 | 0 |
Net Income Before Taxes | 348 | 269 | 222.729 | 211.992 | 176.289 |
Net Income After Taxes | 268 | 205 | 175.331 | 186.82 | 167.627 |
Net Income Before Extra. Items | 268 | 205 | 175.331 | 186.82 | 167.627 |
Net Income | 268 | 205 | 175.331 | 186.82 | 167.627 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | 268 | 205 | 175.331 | 186.82 | 167.627 |
Income Available to Common Incl. Extra. Items | 268 | 205 | 175.331 | 186.82 | 167.627 |
Diluted Net Income | 268 | 205 | 175.331 | 186.82 | 167.627 |
Diluted Weighted Average Shares | 66.1843 | 65.4648 | 65.2085 | 65.1821 | 64.7144 |
Diluted EPS Excluding Extraordinary Items | 4.0493 | 3.13145 | 2.68877 | 2.86612 | 2.59026 |
Dividends per Share - Common Stock Primary Issue | 1.6 | 1.55 | 1.5 | 0 | 1.5 |
Diluted Normalized EPS | 4.29365 | 3.17802 | 2.68877 | 2.89992 | 2.62699 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 449 | 409 | 361 | 384 | 401 |
Revenue | 449 | 409 | 361 | 384 | 401 |
Cost of Revenue, Total | 167 | 155 | 141 | 158 | 160 |
Gross Profit | 282 | 254 | 220 | 226 | 241 |
Total Operating Expense | 384 | 356 | 307 | 343 | 304 |
Selling/General/Admin. Expenses, Total | 169 | 143 | 126 | 150 | 127 |
Research & Development | 44 | 37 | 28 | 31 | 28 |
Other Operating Expenses, Total | 3 | 1 | -1 | 4 | -11 |
Operating Income | 65 | 53 | 54 | 41 | 97 |
Interest Income (Expense), Net Non-Operating | -19 | -9 | 2 | 55 | -12 |
Net Income Before Taxes | 46 | 44 | 56 | 96 | 85 |
Net Income After Taxes | 38 | 34 | 43 | 74 | 65 |
Net Income Before Extra. Items | 38 | 34 | 43 | 74 | 65 |
Net Income | 38 | 34 | 43 | 74 | 65 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | 38 | 34 | 43 | 74 | 65 |
Income Available to Common Incl. Extra. Items | 38 | 34 | 43 | 74 | 65 |
Diluted Net Income | 38 | 34 | 43 | 74 | 65 |
Diluted Weighted Average Shares | 80.1183 | 69.5922 | 66.1808 | 66.2002 | 66.1946 |
Diluted EPS Excluding Extraordinary Items | 0.4743 | 0.48856 | 0.64974 | 1.11782 | 0.98195 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 1.6 | 0 |
Diluted Normalized EPS | 0.54647 | 0.76615 | 0.85858 | 1.11782 | 0.98195 |
Unusual Expense (Income) | 1 | 20 | 13 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1031 | 774 | 751.615 | 586.569 | 494.438 |
Cash and Short Term Investments | 441 | 311 | 371.325 | 185.867 | 177.02 |
Cash & Equivalents | 441 | 311 | 371.325 | 185.867 | 177.02 |
Total Receivables, Net | 260 | 207 | 207.455 | 212.815 | 173.728 |
Accounts Receivable - Trade, Net | 223 | 180 | 194.018 | 197.651 | 156.042 |
Total Inventory | 305 | 237 | 159.823 | 173.76 | 132.338 |
Prepaid Expenses | 25 | 19 | 13.013 | 14.128 | 11.352 |
Other Current Assets, Total | -0.001 | -0.001 | |||
Total Assets | 2339 | 1992 | 1434.44 | 1335.69 | 1003.2 |
Property/Plant/Equipment, Total - Net | 162 | 128 | 103.656 | 112.253 | 48.63 |
Property/Plant/Equipment, Total - Gross | 385 | 324 | 201.79 | 215.717 | 130.51 |
Accumulated Depreciation, Total | -223 | -196 | -98.134 | -103.464 | -81.88 |
Goodwill, Net | 794 | 741 | 290.209 | 315.869 | 186.055 |
Intangibles, Net | 308 | 313 | 250.787 | 260.047 | 192.654 |
Long Term Investments | 21 | 14 | 12.254 | 16.614 | 17.368 |
Note Receivable - Long Term | 0.003 | ||||
Other Long Term Assets, Total | 23 | 22 | 25.92 | 44.335 | 64.055 |
Total Current Liabilities | 417 | 313 | 217.364 | 212.272 | 173.397 |
Accounts Payable | 57 | 56 | 51.236 | 41.461 | 54.764 |
Payable/Accrued | 0.001 | ||||
Accrued Expenses | 58.479 | 69.334 | 60.411 | ||
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 25 | 23 | 21.214 | 21.231 | |
Other Current Liabilities, Total | 335 | 234 | 86.435 | 80.245 | 58.222 |
Total Liabilities | 702 | 621 | 444.403 | 460.184 | 301.023 |
Total Long Term Debt | 192 | 180 | 140.677 | 147.647 | 109.4 |
Deferred Income Tax | 71 | 73 | 32.838 | 28.884 | 14.78 |
Other Liabilities, Total | 22 | 55 | 53.524 | 71.381 | 3.446 |
Total Equity | 1637 | 1371 | 990.038 | 875.503 | 702.18 |
Common Stock | 93 | 92 | 90.969 | 90.63 | 89.953 |
Retained Earnings (Accumulated Deficit) | 1229 | 1063 | 956.114 | 781.121 | 692.104 |
Other Equity, Total | 34 | -50 | -116.547 | 3.752 | -79.877 |
Total Liabilities & Shareholders’ Equity | 2339 | 1992 | 1434.44 | 1335.69 | 1003.2 |
Total Common Shares Outstanding | 65.9838 | 65.9838 | 65.2018 | 64.7144 | 64.7144 |
Long Term Debt | 150 | 150 | 110 | 109.55 | 109.4 |
Capital Lease Obligations | 42 | 30 | 30.677 | 38.097 | |
Additional Paid-In Capital | 281 | 266 | 59.502 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1379 | 1288 | 1034 | 1031 | 1008 |
Cash and Short Term Investments | 501 | 444 | 426 | 441 | 388 |
Cash & Equivalents | 501 | 444 | 426 | 441 | 388 |
Total Receivables, Net | 370 | 408 | 306 | 285 | 314 |
Accounts Receivable - Trade, Net | 279 | 308 | 229 | 223 | 253 |
Total Inventory | 508 | 436 | 302 | 305 | 306 |
Other Current Assets, Total | |||||
Total Assets | 5001 | 5002 | 2362 | 2339 | 2306 |
Property/Plant/Equipment, Total - Net | 193 | 200 | 98 | 162 | 138 |
Goodwill, Net | 2491 | 2575 | 801 | 794 | 804 |
Intangibles, Net | 888 | 885 | 376 | 308 | 319 |
Long Term Investments | 19 | 20 | 20 | 21 | 15 |
Other Long Term Assets, Total | 31 | 34 | 33 | 23 | 22 |
Total Current Liabilities | 728 | 689 | 377 | 417 | 402 |
Accounts Payable | 174 | 139 | 64 | 57 | 74 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 30 | 22 | 23 | 25 | 23 |
Other Current Liabilities, Total | 524 | 528 | 290 | 335 | 305 |
Total Liabilities | 1311 | 1257 | 674 | 702 | 707 |
Total Long Term Debt | 221 | 196 | 196 | 192 | 174 |
Long Term Debt | 150 | 150 | 150 | 150 | 150 |
Capital Lease Obligations | 71 | 46 | 46 | 42 | 24 |
Deferred Income Tax | 202 | 212 | 86 | 71 | 73 |
Other Liabilities, Total | 160 | 160 | 15 | 22 | 58 |
Total Equity | 3690 | 3745 | 1688 | 1637 | 1599 |
Common Stock | 112 | 112 | 93 | 93 | 92 |
Additional Paid-In Capital | 2291 | 2289 | 282 | 281 | 277 |
Retained Earnings (Accumulated Deficit) | 1241 | 1199 | 1273 | 1229 | 1155 |
Other Equity, Total | 46 | 145 | 40 | 34 | 75 |
Total Liabilities & Shareholders’ Equity | 5001 | 5002 | 2362 | 2339 | 2306 |
Total Common Shares Outstanding | 80.0082 | 79.9379 | 65.9838 | 65.9838 | 65.9838 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 348 | 269 | 222.729 | 211.992 | 176.289 |
Cash From Operating Activities | 341 | 353 | 279.047 | 211.807 | 155.005 |
Cash From Operating Activities | 102 | 75 | 73.904 | 74.372 | 39.412 |
Non-Cash Items | -17 | 4 | -11.661 | 2.129 | -11.727 |
Cash Taxes Paid | 52 | 16 | 15.083 | 9.925 | 9.314 |
Cash Interest Paid | 5 | 3 | 3.339 | 2.86 | 1.738 |
Changes in Working Capital | -92 | 5 | -5.925 | -76.686 | -48.969 |
Cash From Investing Activities | -84 | -341 | -61.32 | -85.676 | -178.411 |
Capital Expenditures | -70 | -56 | -60.941 | -45.454 | -47.158 |
Other Investing Cash Flow Items, Total | -14 | -285 | -0.379 | -40.222 | -131.253 |
Cash From Financing Activities | -133 | -82 | -22.723 | -119.205 | 19.342 |
Total Cash Dividends Paid | -102 | -98 | 0 | -97.803 | -90.6 |
Issuance (Retirement) of Debt, Net | -30 | 16 | -22.723 | -21.402 | 109.942 |
Foreign Exchange Effects | 7 | 9 | -9.547 | 1.921 | 6.821 |
Net Change in Cash | 131 | -61 | 185.457 | 8.847 | 2.757 |
Financing Cash Flow Items | -1 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 56 | 348 | 252 | 167 | 92 |
Cash From Operating Activities | 11 | 341 | 242 | 145 | 57 |
Cash From Operating Activities | 26 | 102 | 74 | 49 | 23 |
Non-Cash Items | -3 | -17 | 28 | 23 | 5 |
Cash Taxes Paid | 39 | 52 | 38 | 27 | 15 |
Changes in Working Capital | -68 | -92 | -112 | -94 | -63 |
Cash From Investing Activities | -19 | -84 | -49 | -32 | -14 |
Capital Expenditures | -19 | -70 | -49 | -31 | -14 |
Other Investing Cash Flow Items, Total | 0 | -14 | 0 | -1 | 0 |
Cash From Financing Activities | -7 | -133 | -127 | -119 | -6 |
Issuance (Retirement) of Debt, Net | -7 | -30 | -25 | -17 | -6 |
Foreign Exchange Effects | 0 | 7 | 12 | 8 | 2 |
Net Change in Cash | -15 | 131 | 78 | 2 | 39 |
Total Cash Dividends Paid | 0 | -102 | -102 | -102 | 0 |
Financing Cash Flow Items | -1 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Kohlberg Kravis Roberts & Co. L.P. | Private Equity | 16.85 | 13481379 | 13481379 | 2023-08-31 | MED |
SEB Investment Management AB | Investment Advisor | 7.19 | 5752589 | 190157 | 2023-08-31 | LOW |
Didner & Gerge Fonder AB | Investment Advisor | 5.1902 | 4152571 | 150000 | 2023-10-17 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 4.31 | 3448353 | -32099 | 2023-08-31 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 4.22 | 3376345 | -23874 | 2023-08-31 | LOW |
ODIN Forvaltning AS | Investment Advisor | 3.7496 | 3000000 | 0 | 2023-09-30 | LOW |
Fjärde AP-Fonden | Pension Fund | 3.37 | 2696276 | 10736 | 2023-08-31 | LOW |
Swedbank Robur Fonder AB | Investment Advisor/Hedge Fund | 3.2497 | 2600000 | 0 | 2023-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.96 | 2368242 | 39015 | 2023-08-31 | LOW |
Lannebo Fonder AB | Investment Advisor/Hedge Fund | 2.7053 | 2164438 | 0 | 2022-12-31 | LOW |
Första AP-Fonden | Pension Fund | 2.36 | 1888193 | 559480 | 2023-08-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.14 | 1712175 | 154251 | 2023-08-31 | LOW |
Danske Bank Asset Management | Investment Advisor | 1.5507 | 1240672 | 30000 | 2023-09-30 | LOW |
TIN Fonder | Investment Advisor | 1.4 | 1120115 | 100151 | 2023-08-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.39 | 1112114 | -62397 | 2023-08-31 | LOW |
Tredje AP Fonden | Pension Fund | 1.2969 | 1037604 | -1033099 | 2023-06-30 | MED |
Montanaro Asset Management Limited | Investment Advisor | 1.22 | 976100 | 72122 | 2023-08-31 | LOW |
M&G Investment Management Ltd. | Investment Advisor | 1.2 | 960098 | 75915 | 2023-08-31 | LOW |
Andra AP-Fonden | Pension Fund | 1.02 | 816083 | -160477 | 2023-08-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1 | 800082 | 28072 | 2023-08-31 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biotage Company profile
Biotage is a Sweden-based Life Science company, specialising in separation and synthesis solutions. The company’s offering comprises three distinct product lines. The Organic Chemistry line seeks to rationalise the development of drugs by purifying substances that will become new drugs. The Analytical Chemistry line aims to reinvent the sample analysis. The Industrial Product line offers innovative systems and consumables that separate substances during the large-scale production. All product lines are available across Europe and the US by the Biotage sales organisation or by distributors. Headquartered in Uppsala, Sweden, Biotage trades on the NASDAQ Stockholm under the BIOT ticker. Find out the latest BIOT stock news at Capital.com.Industry: | Medical Diagnostic & Testing Equipment |
Vimpelgatan 5
UPPSALA
UPPSALA 753 18
SE
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com